|1.||Zhao, Hongjuan: 2 articles (11/2010 - 01/2009)|
|2.||Peehl, Donna M: 2 articles (11/2010 - 01/2009)|
|3.||Flamand, Vincent: 2 articles (11/2010 - 01/2009)|
|4.||Noveanu, Lavinia: 1 article (09/2015)|
|5.||Dănilă, Maria D: 1 article (09/2015)|
|6.||Mirica, Silvia N: 1 article (09/2015)|
|7.||Privistirescu, Andreea I: 1 article (09/2015)|
|8.||Sturza, Adrian: 1 article (09/2015)|
|9.||Muntean, Danina M: 1 article (09/2015)|
|10.||Duicu, Oana M: 1 article (09/2015)|
|1.||Body Weight (Weight, Body)
01/01/1988 - "Although daily (4 h) food intake was not significantly less in clorgyline-treated animals relative to saline-treated controls, body weight gain was significantly less in clorgyline-treated animals relative to controls. "
01/30/1994 - "with 5 mg/kg body weight of clorgyline or 50 mg/kg body weight of pargyline in 0.9% NaCl until the end of the experiment. "
04/01/2009 - "Thus, the aim of the present study was to clarify the potential interference of a specific inhibition of MAO-A by clorgyline, on the deleterious effects produced by a binge administration of a neurotoxic dose of MDMA (10 mg MDMA/kg of body weight, intraperitoneally, every 2 hours in a total of four administrations) to an adolescent rat model. "
05/01/2008 - "Mice treated with AMPT, l-DOPA, or clorgyline + METH developed hyperthermia to the same extent as animals treated with METH alone, whereas mice treated with reserpine + METH were hypothermic, suggesting that the effects of alterations in cytoplasmic DA on METH neurotoxicity were not strictly mediated by changes in core body temperature. "
04/01/2009 - "Considering that hyperthermia has been shown to contribute to the neurotoxic effects of MDMA, another objective of the present study was to evaluate the body temperature changes mediated by MDMA with a MAO-A selective inhibition by clorgyline. "
07/01/1998 - "The purpose of this study was: (1) to investigate the effect of the anticonvulsant agent, milacemide, a glycine pro-drug on STR-allodynia; (2) to compare this effect with that of milacemide on normal nociception (without STR); and (3) to determine the sensitivity of the anti-allodynic effect of milacemide to pretreatment with selective monoamine oxidase (MAO)-A (clorgyline) and MAO-B (L-deprenyl) inhibitors. "
|4.||Body Temperature Changes
01/01/1986 - "At the same time chlorgyline had an overall protective effect, increasing two-fold the period prior to the development of oxygen convulsions. "
10/01/1987 - "The possibility is shown to prevent oxygen seizures not only with irreversible MAO-A inhibitors (clorgyline), but also with reversible ones (moclobemide)."
05/01/1986 - "A preliminary injection of clorgyline (a monoamine oxidase type A inhibitor) before hyperoxic exposure leads to a significant removal of oxygen seizures and prevents changes in the cerebral spermidine and histamine content observed in the unprotected animals. "
10/01/1980 - "All six drugs also potentiated tryptamine in producing body tremors and clonic seizures, the rank order of potency being tranylcypromine (0.081)>clorgyline (0.14) greater than or equal to pheniprazine (0.15)>pargyline (1.97)>deprenyl (15.5)>nialamide (18.7). "
09/01/1985 - "Repeated administration of drugs that increase tryptaminergic neurotransmission antagonized the increase in latency to onset and the duration of postdecapitation convulsions (PDCs) induced by an acute 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) injection; Zimelidine (2 X 5 mg kg-1), fluoxetine (2 X 5 mg kg-1), amiflamine (2 X 2.5 mg kg-1) and alpha-ethyltryptamine (2 X 2.5 mg kg-1) administered orally over 10 days caused a substantial blockade of the increase in latency to onset and duration of PDCs following 5-MeODMT, whereas alaproclate (2 X 5 mg kg-1), clorgyline (1 X 1 mg kg-1) and pargyline (2 X 2.5 mg kg-1) caused a lesser blockade. "
|1.||Monoamine Oxidase (MAO)
|4.||Glycine (Aminoacetic Acid)
|6.||Pargyline (Pargyline Hydrochloride)
|9.||Serotonin (5 Hydroxytryptamine)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Induced Hyperthermia (Thermotherapy)